Moreover, Ginkgetin can interact with gain‐of‐function mutant STING proteins hSTINGN154S and hSTINGV155M, which have been reported to cause spontaneous activation of STING and are associated with STING‐associated vasculopathy with onset in infancy (SAVI).[46, 51] In future studies, we will further investigate the potential therapeutic effects of Ginkgetin on SAVI and other related diseases, such as Aicardi‐Goutières syndrome (AGS) and systemic lupus erythematosus (SLE). This evidence concerns the gene STING1 and Aicardi-Goutieres syndrome.